Merck KGaA to Acquire Silence Therapeutics in All-Cash Deal
Silence Therapeutics said it agreed to be purchased by Germany's Merck KGaA in an all-cash deal for its gene-silencing technology. The headline states Merck is paying a 130% premium.
Germany's Merck KGaA has agreed to acquire London-based Silence Therapeutics in an all-cash transaction, paying a substantial premium for the company's gene-silencing technology. The key question for investors is whether the deal makes sense. Silence said Monday that it had agreed to be acquired through a…